Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients
Joshua T. Kantrowitz, Daniel C. Javitt, Robert Freedman, Pejman Sehatpour, Lawrence S. Kegeles, Marlene Carlson, Tarek Sobeih, Melanie M. Wall, Tse‐Hwei Choo, Blair Vail, Jack Grinband, Jeffrey A. Lieberman
Topics & Concepts
PsychologyPlaceboSchizoaffective disorderRandomized controlled trialRepeatable Battery for the Assessment of Neuropsychological StatusSchizophrenia (object-oriented programming)Scale for the Assessment of Negative SymptomsCrossover studyBrief Psychiatric Rating ScalePsychosisInternal medicinePsychiatryMedicineNeuropsychologyCognitionAlternative medicinePathologyNicotinic Acetylcholine Receptors StudyReceptor Mechanisms and SignalingTryptophan and brain disorders